-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, TAO6IbhdsOy13ggEAOeieY83ZJJu7DidCJ1nWFgSO8MQo46OQNzqaNRpkIUBbMPd OTK85UCJ+XkLK/BcSfD/ag== 0000950124-06-005864.txt : 20061010 0000950124-06-005864.hdr.sgml : 20061009 20061010160914 ACCESSION NUMBER: 0000950124-06-005864 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20061004 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20061010 DATE AS OF CHANGE: 20061010 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HELIX BIOMEDIX INC CENTRAL INDEX KEY: 0000831749 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 912099117 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 033-20897 FILM NUMBER: 061137938 BUSINESS ADDRESS: STREET 1: 22122 20TH AVE SE CITY: BOTHELL STATE: WA ZIP: 98021 BUSINESS PHONE: 425 402 8400 MAIL ADDRESS: STREET 1: 22122 20TH AVE SE CITY: BOTHELL STATE: WA ZIP: 98021 FORMER COMPANY: FORMER CONFORMED NAME: CARTEL ACQUISITIONS INC DATE OF NAME CHANGE: 19890718 FORMER COMPANY: FORMER CONFORMED NAME: CARIBBEAN ACQUISTIONS INC DATE OF NAME CHANGE: 19880725 8-K 1 v24129e8vk.htm FORM 8-K e8vk
 

 
 
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 4, 2006
 
HELIX BIOMEDIX, INC.
(Exact name of registrant as specified in its charter)
 
         
DELAWARE   033-20897-D   91-2099117
         
(State or other jurisdiction   (Commission   (IRS Employer
of incorporation or organization)   File Number)   Identification No.)
22122 20th Avenue S.E., Suite 148
Bothell, Washington 98021
(425) 402-8400
(Address and telephone number of registrant’s principal executive offices)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 

Item 1.01 Entry into a Material Definitive Agreement.
On October 4, 2006, Helix BioMedix, Inc. (the “Company”) entered into a Second Amendment to Lease (the “Second Lease Amendment”) with Teachers Insurance & Annuity Association of America, Inc. in connection with the premises located at 22122 20th Avenue SE, Bothell, Washington 98021. The Second Lease Amendment amends the Lease dated August 14, 2001 (the “Initial Lease”), as amended by the First Amendment to Lease dated December 6, 2005. Pursuant to the terms of the Second Lease Amendment, the Company will lease 2,246 square feet of office space (the “Expansion Premises”) in addition to the initial premises comprising 3,038 square feet of office and warehouse space (the “Initial Premises”). The Second Lease Amendment extends the term of the Initial Lease for an additional 36 months, commencing December 1, 2006. Base monthly rent for the rental premises (including the Initial Premises and the Expansion Premises) is $6,064 for the initial 12 months, $6,246 for months 13 through 24, and $6,433 for months 25 through 36. The Second Lease Amendment includes an option of the Company to extend the term of the Initial Lease for an additional 36 months with respect to the Initial Premises only.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
             
 
      HELIX BIOMEDIX, INC.    
 
           
Dated: October 10, 2006
  By:   /s/ David H. Kirske
 
David H. Kirske 		   
 
      Vice President and Chief Financial Officer    

 

-----END PRIVACY-ENHANCED MESSAGE-----